Subscribe free

HPB & Spleen ·

Adjuvant therapy improves recurrence-free survival in HCC patients

Camrelizumab plus apatinib in a real-world setting has shown significant benefits in recurrence-free survival (RFS) for patients with hepatocellular carcinoma (HCC) with microvascular invasion following radical resection. The comparison between adjuvant therapy (99 patients) and observation (172 patients) indicated a hazard ratio of 0.52 for RFS improvement (p<0.001). However, overall survival did not significantly differ (hazard ratio 0.62; p=0.079). Grade 3 or 4 treatment-related adverse events occurred in 20.7% of treated patients.

Journal Article by Ouyang J, Yang Y (…) Zhao H et 8 al. in Hepatobiliary Surg Nutr

2024 Hepatobiliary Surgery and Nutrition. All rights reserved.

read the whole article in Hepatobiliary Surg Nutr

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in HPB & Spleen.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in HPB & Spleen

The latest stitches

Surg Endosc6 Nov 2026

A new cut for robotic liver surgery

A close-to-open cutting method was used for robotic liver resection, with no bile leaks and shorter hospital stays than after laparoscopy.

Surg Endosc6 Nov 2026

Robotic bile duct stone surgery: fewer complications

Removing large common bile duct stones with a robot rather than laparoscopically was linked to fewer complications and shorter hospital stays, at a higher cost, in a study from one Chinese hospital.

All papers in HPB & Spleen →